Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: An interim analysis of a post-marketing surveillance

Hideto Kameda(Toho University), Yoshiya Tanaka(University of Occupational and Environmental Health Japan), Toshiya Takahashi(Tohoku University), Sadatomo Tasaka(Hirosaki University), Naoki Soeda(Asahi Kasei (Japan)), Katsuhisa Suzuki(Sanofi (Japan))
Modern Rheumatology
June 8, 2023
10.1093/mr/road055
Cited by 4

Related Papers

Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|413
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
|The Lancet|2023|164
A Randomized, <scp>Placebo‐Controlled</scp> Phase <scp>III</scp> Extension Trial of the <scp>Long‐Term</scp> Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
|Arthritis & Rheumatology|2022|151